Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. CMND-100 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 4 original sources each. MEAI appears in 1 tracked Biotech story from July 11, 2026.
Last mentioned: Jul 11, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. CMND-100 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 4 original sources each. MEAI appears in 1 tracked Biotech story from July 11, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MEAI. Shared-story counts are live from our verified record — not editorial picks.
Clearmind Medicine submitted a response to an HHS RFI highlighting its clinical-stage candidate CMND-100, an MEAI-based neuroplastogen for Alcohol Use Disorder. The drug engages 5-HT1A pathways without hallucinogenic effects, offering a novel mechanism for addiction treatment.
Source: Nynewscast · Financialcontent
MEAI is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
